CEPHULAC
LOE ApproachingNDAORAL, RECTALSOLUTIONPriority Review
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEPHULAC is an oral/rectal solution small molecule approved in 1976 for treatment of hepatic encephalopathy and constipation. The mechanism of action involves osmotic laxative properties and alteration of colonic pH to reduce ammonia absorption. It is a well-established, legacy therapeutic indicated for patients with liver disease or functional bowel disorders.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand team likely focused on retention and cost management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CEPHULAC offers limited career growth opportunity given its LOE-approaching status and minimal linked job openings. Roles on this product emphasize defensive commercial strategy, payer management, and cost optimization rather than market expansion or innovation.
Brand ManagerField Sales Representative
Worked on CEPHULAC at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.